WORXE Worlds Online Inc

MariMed Begins Trading on OTCQX Best Market as MRMD

MariMed Begins Trading on OTCQX Best Market as MRMD

  • The OTCQX® Best Market is top tier of OTC Markets; provides exchange-quality trading experience with superior information availability for investors
  • MRMD to begin trading on OTCQX today
  • MRMD ticker symbol remains unchanged

NORWOOD, Mass., Aug. 15, 2019 (GLOBE NEWSWIRE) -- . (OTCQX: MRMD), a premier cannabis and hemp multi-state operator focused on health and wellness, has qualified to trade on the OTCQX® Best Market.

The OTCQX Best Market is for established, investor-focused U.S. and international companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice for corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosures, and have a professional third-party sponsor introduction.

 “We expect trading on the OTCQX Best Market to elevate our profile in the investment community, improving liquidity and broadening our shareholder base,” said MariMed CEO, Bob Fireman. “This represents another next step in our capital market and corporate development strategy designed to build shareholder value and advance MariMed as a leader in cannabis for health and wellness.”

The company markets the highest quality of cannabis and hemp products nationwide with a portfolio of innovative brands. It recently second quarter 2019 revenues of $25.7 million, up 775%, with net income of $4.7 million.

"We're excited to welcome MariMed to the OTCQX Best Market," said Jason Paltrowitz, EVP of corporate services at OTC Markets Group. “After trading on our OTCQB Venture Market since 2017, MariMed's graduation to the OTCQX Best Market demonstrates how companies can leverage the OTC Markets Group tiers to build visibility and long-term shareholder value."

MariMed begins trading today on the OTCQX under the symbol “MRMD.”  Investors can find current financial disclosures and real-time Level II quotes for the company at .

About MariMed

MariMed, a multi-state cannabis operator, is dedicated to improving the health and wellness of people through the use of cannabinoids and cannabis products.  The Company develops, owns and manages seed to sale state licensed cannabis facilities which are models of excellence in horticultural principles, cannabis cultivation, cannabis infused products, and dispensary operations.  MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units.  MariMed is at the forefront of science and innovation through research developed by its lab technicians and medical advisors resulting in industry leading products and brands, including “Kalm Fusion” and “Betty’s Eddies”.  These precision dosed products are focused on specific medical symptoms which are licensed and distributed across the country.  

In 2019, with enactment of the 2018 US Farm Bill, MariMed formed MariMed Hemp, a wholly owned subsidiary, to leverage its seed to sale cannabis platform and experience into the emerging hemp-based CBD industry.  The Company acquired a significant stake in Kentucky-based GenCanna Global, a national and international leading cultivator, producer, and distributer of hemp and GMP quality CBD oils and isolates.  With this strategic relationship MariMed Hemp has developed and is marketing a portfolio of CBD brands and products to multiple retailers and direct to consumers both domestically and internationally. The Company recently launched its Hemp Engine™ “store within a store” distribution platform for retailers.  MariMed Hemp is actively pursuing other hemp industry business opportunities with genetics, farming, biomass, and new and innovative technologies.

For additional information, visit . 

Facebook:  ™

About OTC Markets Group Inc.

(OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

To learn more, visit .

Company Contact

Jon Levine, CFO

MariMed Inc.

Tel (781) 559-8713

Media & Investor Contact

Ronald Both or Jonathan Leuchs

CMA  

Tel (949) 432-7566

 

EN
15/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Worlds Online Inc

 PRESS RELEASE

MariMed Extends Series B Preferred Stock Obligation Through 2031, Stre...

MariMed Extends Series B Preferred Stock Obligation Through 2031, Strengthening Capital Structure NORWOOD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today that it has entered into a Restructuring and Exchange Agreement (the “Agreement”) with the holders (the “Holders”) of its $14.725 million Series B Convertible Preferred Stock (the “Series B Obligation”). The restructuring extends the maturity of the Company’s obligations on favorable market term...

 PRESS RELEASE

MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date

MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date NORWOOD, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its fourth quarter and full year 2025 financial results on March 11, 2026 after the markets close. Management will host a conference call on March 12, 2026 at 8:00 a.m. EDT to discuss financial results. A webcast will be available and can be accessed via MariMed’s Investor Relations website at . A playback of the call will...

 PRESS RELEASE

MariMed’s Betty’s Eddies™ Introduces New Limited-Edition Valentine’s S...

MariMed’s Betty’s Eddies™ Introduces New Limited-Edition Valentine’s Seasonal, Berry In Love Betty The Brand’s First-Ever Swirled Chew Combines Strawberry and Chocolate Flavors Plus CBG and Horny Goat Weed for Libido-enhancing Fun NORWOOD, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ™, the all-natural cannabis fruit chews handcrafted for specific health and wellness effects, is expanding its lineup with a new limited-edition batch of strawberry chocolate chews in time for Valentine’s Day: Berry In Love Betty. Betty’s Eddies is one of the top-selling and award-winning brands developed and d...

 PRESS RELEASE

MariMed Launches Hemp-Derived THC Products Under its Vibations™ Brand ...

MariMed Launches Hemp-Derived THC Products Under its Vibations™ Brand in Rhode Island NORWOOD, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- (“MariMed,” “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced the launch of a hemp-derived THC version of its hydrating drink mix brand in Rhode Island. The launch represents a capital-efficient opportunity for the Company to expand Vibations into the rapidly growing hemp THC beverage category through an established retail channel, without incremental cultivation or retail infrast...

 PRESS RELEASE

MariMed Statement on Historic Rescheduling of Cannabis

MariMed Statement on Historic Rescheduling of Cannabis NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the following statement from CEO Jon Levine today. “We commend President Trump and the Trump Administration for reclassifying cannabis as a Schedule III drug. This is the single greatest cannabis reform in US history and will have far-reaching benefits for years to come. Most important, the reclassification means the Federal government officially a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch